Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

38.87+0.04 (+0.10%)

At close: 4:00PM EDT

38.87 0.00 (0.00%)
After hours: 04:32PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	38.83
Open	38.92
Bid	38.10 x 800
Ask	39.45 x 1200
Day's Range	38.24 - 39.18
52 Week Range	27.21 - 56.40
Volume	451,972
Avg. Volume	762,596

Market Cap	5.533B
Beta (5Y Monthly)	1.44
PE Ratio (TTM)	24.77
EPS (TTM)	1.57
Earnings Date	Nov 02, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	12.05

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

-3% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for HALO

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Halozyme Therapeutics, Inc.
HALO: Lowering target price to $39.00HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $39.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
Rating
Fair Value
Economic Moat
11 days agoArgus Research

All

News

Press Releases

Research Reports

PR Newswire
Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2021 on November 2 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the third quarter ended September 30, 2021, following the close of trading.
Benzinga
Notable Halozyme Therapeutics Insider Trades $2.7M In Company Stock
Helen Torley, President And CEO at Halozyme Therapeutics (NASDAQ:HALO), made a large buy and sell of company shares on October 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Helen Torley exercised options to purchase 50,000 Halozyme Therapeutics shares at a price of $14.66 per share for a total of $733,000 on October 4. They then sold their shares on the same day in the open market. They sold at prices ranging from $3
Benzinga
Notable Halozyme Therapeutics Insider Trades $1.6M In Company Stock
Michael J Labarre, SVP And Chief Technical Officer at Halozyme Therapeutics (NASDAQ:HALO), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Michael J Labarre exercised options to purchase 29,450 Halozyme Therapeutics shares at a price of $13.10 per share for a total of $385,795 on October 1. They then sold their shares on the same day in the open market. They sold a